Itruvone
 | This article may require cleanup to meet Wikipedia's quality standards. The specific problem is: Too much unverified information, purported clinical trial results do not have any references, confirmation of chemical identity needed, etc. (September 2018) |
 | This article's factual accuracy is disputed. (September 2018) |
 | This article needs more reliable medical references for verification or relies too heavily on primary sources. (September 2018) |  |
 | |
| Clinical data | |
|---|---|
| Other names | PH10A; PH10 NS |
| Routes of administration | Intranasal |
| Legal status | |
| Legal status |
|
| Chemical and physical data | |
| Formula | C20H32O |
| Molar mass | 288.475 g/mol g·mol−1 |
| 3D model (JSmol) | |
| Density | 1.056 g/cm³ g/cm3 |
| Boiling point | 336.1 °C (637.0 °F) [dubious – discuss] |
| Solubility in water | 30.494 mg/L mg/mL (20 °C) |
| |
| |
PH10 is a purported vomeropherine that is under development by Pherin Pharmaceuticals as a nasal spray for the treatment of major depressive disorder.[1][2] In a small phase II clinical study, PH10 demonstrated rapid antidepressant effects, taking effect by one week.[citation needed] In addition, the effect sizes were found to be quite large (Cohen’s d value of 1.01 for high-dose PH10 and placebo, and Cohen’s d value of 0.71 for low-dose PH10 versus placebo).[citation needed] 60–80% of patients achieved remission from depression.[citation needed] PH10 was well-tolerated, with adverse effects including somnolence, nasal irritation, and headache.[citation needed]
Despite claiming that this drug has been through clinical studies, there is no objective or non-biased information available on this drug. It is not recognized as having gone through clinical trials on ClinicalTrials.gov in the United States. Pherin Pharmaceuticals only has two completed clinical trials that are recognized by the U.S. government [3] -- both of which were for the drug PH94B. With the claim that this drug is between 60%-80% effective as an anti-depressive treatment, over the course of one week, it may be dangerous for individuals interested in research chemicals, as there is no evidence at this time to support their claims. Its toxicity is not known, and may cause major health problems due to the lack of an FDA approved clinical trial designed to establish safety (phase one clinical trial).
See also
References
- ^ Liebowitz, MR; Nicolini, H; Monti, L; Hanover, R (2013). "PH 10 may be a new rapidly acting intranasally administered antidepressant". American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, FL.
{{cite journal}}: Cite journal requires|journal=(help) - ^ Jancin, Bruce (2013). "Novel intranasal antidepressant shows results after 1 week". Clinical Psychiatry News. Retrieved 13 January 2016.
- ^ "Search of: Pherin Pharmaceuticals - List Results - ClinicalTrials.gov".
External links
 | This article about a steroid is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |